Clinical trials: West Nile Fever
West Nile Fever
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease.
- Trial name
- NCT00442169
- Testing
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose
- Where
- 5 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
West Nile Neuroinvasive Disease, West Nile Virus Infection
Treatment of West Nile Virus With MGAWN1
This study will test a drug called MGAWN1 for the treatment of West Nile infections.
- Conditions
- West Nile Neuroinvasive Disease, West Nile Virus Infection, Encephalitis, Meningitis
- Trial name
- PARADIGM (NCT00927953)
- Testing
- MGAWN1
- Volunteers
- 13 people
- Sponsor
- MacroGenics
West Nile Fever
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
- Trial name
- WinVax004 (NCT00746798)
- Testing
- ChimeriVax-WN02 vaccine
- Where
- 15 sites in United States
- Volunteers
- 479 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company